In this Pharmaceutical Executive video interview, Panna Sharma, CEO, Lantern Pharma, talks about ensuring global access to LP-284, particularly in regions with limited resources

Strategic financing from Oaktree Capital Management and OMERS Life Sciences is expected to support the US launch of ensifentrine, Verona’s promising chronic obstructive pulmonary disease treatment.

The latest news for pharma industry insiders.

Cencora’s vice president of product management, global products & solutions Beth Riggio discusses the issues the industry faces with recalls and how it can improve.

The new care center will offer primary care services to uninsured and underinsured patients in the Wilmington, North Carolina, area.

In this Pharmaceutical Executive video interview, Panna Sharma, CEO, Lantern Pharma, explains which specific endpoints they'll be looking at in the Phase I trial to assess LP-284's potential efficacy and how the insights gained will be fed back into RADR®

In an interview with Pharm Exec Associate Editor Don Tracy, Melissa Lattanzi, VP, Emerging Therapies, Cencora, discusses the unique challenges that developers of cell and gene therapies need to plan for when building their channel strategy.

A Harvard Business School Healthcare Alumni Association Q&A with Dorie Clark, Instructor of Executive Education at the Columbia Business School.

The industry must find a way to balance consumer privacy and a return on investment in pharma marketing.

The latest news for pharma industry insiders.

Joint venture aims to develop up to 10 new cell and gene therapy products targeting areas with high unmet medical needs.

RxLink will incorporate Cost Plus’ prices into its drug pricing platform MedMap.

The catheters approved by the FDA include the Plato 17, a DMSO-compatible microcatheter, and the Socrates 38, an aspiration catheter specifically designed for treating ischemic strokes.

In this Pharmaceutical Executive video interview, Jesse Mendelsohn, senior vice president at Model N, discusses how more granular insights into channel, tracing, and chargeback data can help drugmakers make smarter provider and payer contracting decisions.

The founder and CEO of UpScriptHealth discusses the issues causing the shortage and how recent decisions from the DEA may help solve the issue.

The latest news for pharma industry insiders.

Myhibbin is reportedly the first FDA-approved liquid formulation of mycophenolate, a key immunosuppressant used to prevent organ rejection in transplant recipients.

Significant findings included a 100% biochemical recurrence-free rate at 24 months post-surgery in patients with high-risk localized prostate cancer.

Acceptance of the application was based on promising results from the Phase III CheckMate -67T study, which displayed noninferiority between the oral and intravenous formulations of Opdivo.

Batra will lead the company’s clinical strategy.

The latest news for pharma industry insiders.

Dr. Lewis used the AI-powered device on a patient with severe lumbar stenosis.

In an interview with Pharm Exec Associate Editor Don Tracy, Melissa Lattanzi, VP, Emerging Therapies, Cencora, offers a synopsis on what questions cell and gene therapy developers need to answer to inform their distribution strategy.

In this Pharmaceutical Executive video interview, Jesse Mendelsohn, senior vice president at Model N, talks about the influence of Medicare Part D drug price negotiations on manufacturer go-to-market strategies and decision-making, and the industry’s response to the wider dialogue on pricing transparency.

Deal includes a number of radioligand therapies targeting solid tumors, such as breast, prostate, and lung cancers.